INT144702

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.68
First Reported 2007
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 19
Total Number 22
Disease Relevance 12.87
Pain Relevance 4.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Tst) RNA binding (Tst) plasma membrane (Tst)
Anatomy Link Frequency
B-cell 3
Tst (Mus musculus)
Pain Link Frequency Relevance Heat
antidepressant 415 100.00 Very High Very High Very High
Eae 237 100.00 Very High Very High Very High
antagonist 236 99.32 Very High Very High Very High
depression 150 98.96 Very High Very High Very High
5HT 44 98.76 Very High Very High Very High
Desipramine 3 96.16 Very High Very High Very High
Hippocampus 47 95.80 Very High Very High Very High
Serotonin 126 93.72 High High
sSRI 29 89.32 High High
monoamine 24 80.88 Quite High
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 612 100.00 Very High Very High Very High
Disease 239 100.00 Very High Very High Very High
Sprains And Strains 511 99.80 Very High Very High Very High
Depression 170 98.96 Very High Very High Very High
Stress 66 98.88 Very High Very High Very High
Targeted Disruption 32 98.86 Very High Very High Very High
Myelodysplastic Syndromes 126 98.28 Very High Very High Very High
Acute Myeloid Leukemia 117 98.12 Very High Very High Very High
Apoptosis 54 96.96 Very High Very High Very High
Hypersensitivity 9 95.84 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Immobility or despair behavior produced in both FST and TST are taken as paradigm of depression and antidepressant drugs reduce the immobility period.
Gene_expression (produced) of TST associated with antidepressant, depression and eae
1) Confidence 0.68 Published 2007 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 17570574 Disease Relevance 0.18 Pain Relevance 0.51
In order to determine the role that the stress response and general activity levels might play in the expression of TST behavior, we phenotyped all 33 strains in the Open Field test.
Gene_expression (expression) of TST associated with stress and sprains and strains
2) Confidence 0.60 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012073 Disease Relevance 1.05 Pain Relevance 0.06
The results first indicate that ZnCl2 administered by p.o. route produces an antidepressant-like effect in the TST.
Gene_expression (produces) of TST associated with antidepressant
3) Confidence 0.59 Published 2008 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 18824054 Disease Relevance 0.05 Pain Relevance 0.73
Although we did not identify any gene expression or coding changes that co-segregated with TST performance, we found 2 SNPs near or within Socs2 that, unlike all surrounding SNPs, exhibited the same strain distribution of alleles (A/G) as the haplotype pattern driving the significant SNPster association on MMU10 (Figure 3C).
Gene_expression (performance) of TST associated with sprains and strains
4) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012073 Disease Relevance 1.19 Pain Relevance 0.18
It is possible that a SNP variant in one of these genes is responsible for some of the strain-specific TST phenotypes that we observed.
Gene_expression (phenotypes) of TST associated with sprains and strains
5) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012073 Disease Relevance 0.60 Pain Relevance 0.35
The correlation between our TST values and those of Liu and colleagues was lower (r?
Gene_expression (values) of TST
6) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012073 Disease Relevance 0.75 Pain Relevance 0.03
Nineteen patients in the TST group who either failed to respond or progressed after TST served as their own controls.
Gene_expression (progressed) of TST
7) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.13 Pain Relevance 0
Because both 131I and TST are cleared by the kidneys, these scans must be examined to ensure that abnormal 131I pooling does not happen.
Gene_expression (cleared) of TST
8) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.09 Pain Relevance 0.07
The MDR for patients was 6.5 months for all 131I-TST responders.
Gene_expression (responders) of 131I-TST
9) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.51 Pain Relevance 0
The annualized incidence of AML/MDS was 1.6%/year which is similar to that of patients treated with multiple chemotherapy regimens.29 In a study of 76 patients treated with upfront 131I-TST monotherapy for follicular NHL, no patients developed MDS/AML with a median follow-up of 7.93 years.30 Distinguishing the attributable risk of MDS/AML to chemotherapy or 131I-TST is difficult, although it appears that 131I-TST does not significantly increase the risk of leukemia.29

131I-TST in relapsed B-cell NHL

Gene_expression (monotherapy) of 131I-TST in B-cell associated with leukemia, lymphatic system cancer, myelodysplastic syndromes and acute myeloid leukemia
10) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 2.09 Pain Relevance 0
Concerns of serious immunosuppression from 131I-TST have not been realized despite depletion of circulating B cells for 6 months after therapy.
Gene_expression (immunosuppression) of 131I-TST in B cells
11) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 1.14 Pain Relevance 0
Therefore, one should not be surprised that 131I-TST therapy is effective in disease refractory to RTX.31
Gene_expression (therapy) of 131I-TST associated with disease
12) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.35 Pain Relevance 0
Several important measures of response favored 131I-TST: overall response (OR) of 55% vs 19% (P = 0.002), complete response (CR) of 33% vs 8% (P = 0.012), and median time to progression (TTP) of 6.3 months vs 5.5 months (P = 0.031).
Gene_expression (favored) of 131I-TST
13) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.15 Pain Relevance 0
Few patients lost acquired humoral immunity suggesting that routine revaccination of patients after 131I-TST is unnecessary.28
Gene_expression (unnecessary.28) of 131I-TST
14) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 1.80 Pain Relevance 0
131I-TST is FDA approved for the treatment of relapsed or refractory low grade CD20+ B-cell NHL, including disease refractory to RTX, or transformed NHL.
Gene_expression (transformed) of 131I-TST in B-cell associated with lymphatic system cancer and disease
15) Confidence 0.43 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 1.10 Pain Relevance 0
It is likely that this unique genetic background impacted the phenotypic expression of the knockout, just as the B6 and R3 mice in this study had divergent TST profiles despite expressing similar levels of Gabra3.
Gene_expression (profiles) of TST associated with targeted disruption
16) Confidence 0.42 Published 2010 Journal Mamm Genome Section Body Doc Link PMC2890984 Disease Relevance 0.49 Pain Relevance 0.03
To verify the role of Gabra3 in regulating TST behavior in vivo, mice were treated with SB-205384, a positive modulator of the ?
Gene_expression (behavior) of TST
17) Confidence 0.42 Published 2010 Journal Mamm Genome Section Abstract Doc Link PMC2890984 Disease Relevance 0.44 Pain Relevance 0.15
Finally, the highly aversive situations in the FST or TST provoked greater active avoidance behavior in GSK-3?
Gene_expression (provoked) of TST associated with eae
18) Confidence 0.31 Published 2009 Journal Mol Brain Section Body Doc Link PMC2785804 Disease Relevance 0.59 Pain Relevance 0.17
Furthermore, the results of our TST studies show that the antidepressant-like action of group II mGlu receptor antagonists does not depend on serotonergic system activation, indicating that the mechanism of the action of group II mGlu receptor antagonists differs from that of typical antidepressants, such as SSRIs.
Gene_expression (studies) of TST associated with antidepressant, antagonist and ssri
19) Confidence 0.30 Published 2010 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2981731 Disease Relevance 0.19 Pain Relevance 0.57
The 5HT2A/2C receptor antagonist, ritanserin (0.5 mg/kg), was not active in the TST when given alone, and it did not influence the MGS0039 (3 mg/kg)-induced attenuation of immobility time in the TST in mice [F(1,24)?
Neg (not) Gene_expression (active) of TST associated with antagonist
20) Confidence 0.30 Published 2010 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2981731 Disease Relevance 0 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox